Drug Profile
Research programme: psoriasis therapeutics - Malvern Cosmeceutics
Alternative Names: MCL 007-01Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Malvern Cosmeceutics
- Class
- Mechanism of Action NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Psoriasis in United Kingdom (PO, Tablet)
- 16 Jul 2016 No recent reports of development identified for research development in Psoriasis in United Kingdom (Topical, Gel)
- 28 May 2013 Early research in Psoriasis in United Kingdom (PO)